Gut bacteria pill aims to supercharge cancer fight
NCT ID NCT07383441
Summary
This study is testing whether adding a specific probiotic (MO-03) to standard immunotherapy drugs helps people with advanced kidney cancer live longer without their cancer getting worse. About 718 participants will be randomly assigned to receive either the probiotic or a placebo pill alongside their regular cancer treatment for up to three years. The main goal is to see if the probiotic, which aims to improve gut health, makes the standard immunotherapy work better at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.